Latest news with #TimHerbert
Bloomberg
11 hours ago
- Business
- Bloomberg
ICYMI: Inspire's Big Buyback
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neuro-stimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The company last week cut its revenue guidance for the full year, saying the US commercial launch for Inspire V is going slower than expected. On Monday, however, it announced a $200 million stock buyback plan, which representing 8.5% of the company's current market value, data compiled by Bloomberg show. Tim Herbert, Inspire's Founder, Chairman, President and CEO discusses the reasons for the repurchase program and the health of the company overall. Tim speaks with Tim Stenovec and Carol Massar on Bloomberg Businessweek Daily.
Yahoo
6 days ago
- Business
- Yahoo
Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook
We recently published . Inspire Medical Systems, Inc. (NYSE:INSP) is one of the worst-performing stocks on Tuesday. Inspire Medical nosedived by 32.35 percent on Tuesday to end at $87.91 apiece as investors unloaded portfolios following a disappointing earnings performance in the second quarter of the year, coupled with a lower growth outlook for the full year. This followed the company's swing to a $3.59 million net loss in the second quarter of the year, reversing a $9.8 million net income in the same period last year. Revenues, however, jumped by 10.7 percent to $217 million from $195.88 million in the same comparable period. In the first half, Inspire Medical Systems, Inc. (NYSE:INSP) said it widened its net loss by 183 percent to $600 million from $212 million, while revenues grew by 16 percent to $418 million from $360 million. Commenting on the company's performance, Inspire Medical Systems, Inc. (NYSE:INSP) Chairman and CEO Tim Herbert believed that operational headwinds were just temporary and that actions are underway to address them. Copyright: lenetstan / 123RF Stock Photo For full-year 2025, the company expects revenues to now settle between $900 million and $910 million, lower than the $940 million to $955 million expected previously. While we acknowledge the potential of INSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
6 days ago
- Business
- Business Insider
Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut
Inspire Medical Systems (INSP) stock plummeted on Tuesday following the release of the medical technology company's Q2 2025 earnings report. This started with adjusted earnings per share of 45 cents, compared to Wall Street's estimate of 20 cents. The company's adjusted EPS also increased 40.63% year-over-year from 32 cents. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts' estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S. However, investors' hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that 'the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.' Inspire Medical Systems Guidance Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street's 2025 revenue estimate of $914.74 million. Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months. The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270. Is Inspire Medical Systems Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today's earnings report.
Yahoo
04-08-2025
- Business
- Yahoo
Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last year Achieved gross margin of 84.0% in the second quarter of 2025 Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 million Loss per share was $0.12 in the second quarter of 2025. Adjusted diluted earnings per share was $0.45 Initiated the full launch of the Inspire V neurostimulation system in the U.S. 'The full launch of our FDA-cleared Inspire V system in the U.S. is an important milestone for Inspire. We have been receiving strong positive feedback from both surgeons and patients who value the simplified procedure and excellent patient outcomes enabled by this next generation technology,' said Tim Herbert, Chairman and CEO of Inspire. 'In the near future, we look forward to presenting the clinical evidence collected to date.' 'The broad enthusiasm for Inspire V gives us confidence that it will be a growth engine for the Company. However, the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.' 'Importantly, we believe the operational headwinds are temporary, and actions are underway to address them,' continued Mr. Herbert. 'We remain steadfast in our commitment to serving the many patients who struggle with untreated moderate to severe OSA, delivering strong patient outcomes and executing on our strategy to drive profitable growth and value creation for all stakeholders.' Second Quarter 2025 Financial Results Revenue was $217.1 million for the second quarter, an 11% increase from $195.9 million in the corresponding prior year period. U.S. revenue for the quarter was $207.2 million, an increase of 10% as compared to the prior year quarter. Second quarter revenue outside the U.S. was $9.9 million, an increase of 23% as compared to the second quarter of 2024. Gross margin was 84.0% for the second quarter of 2025 compared to 84.8% in the second quarter of 2024. The decrease is primarily due to a $2.1 million charge associated with excess components inventory related to Inspire IV. Operating expenses were $185.7 million for the second quarter of 2025, as compared to $160.9 million in the corresponding prior year period, an increase of 15%. This increase primarily reflected ongoing investments in the expansion of the U.S. sales organization, patient marketing expenses, and general corporate costs, partially offset by a reduction in R&D. Operating expenses also included an additional one-time charge of $11.2 million of accelerated stock-based compensation expense for employees who are retirement eligible in accordance with changes to the Inspire incentive award plan upon the employee's death, disability, or retirement, and finally, $1.7 million in certain litigation-related legal expenses. These items do not reflect costs associated with our ongoing operations and a reconciliation table has been included at the bottom of this release. Operating loss was $3.3 million for the second quarter of 2025, as compared to operating income of $5.1 million in the prior year period, a decrease of 165%. Net loss was $3.6 million for the second quarter of 2025 as compared to a net income of $9.8 million in the corresponding prior year period. The net loss includes a $4.0 million non-cash impairment of a strategic investment. Adjusted EBITDA for the second quarter of 2025 was $44.1 million as compared to $38.7 million in the corresponding prior year period. The diluted net loss for the second quarter of 2025 was $0.12 per share, as compared to a net income of $0.32 per share in the prior year period. The adjusted net income for the second quarter of 2025 was $0.45 per share. As of June 30, 2025, cash, cash equivalents, and investments were $410.7 million compared to $516.5 million on December 31, 2024. Executive Retirement 'Randy Ban, our Executive Vice President of Patient Access and Therapy Development, recently notified us of his intention to retire on January 30, 2026. During his tenure, Randy has been one of Inspire's most influential leaders, and as our initial commercial leader, he played a significant role in advancing access to Inspire therapy and building a strong, mission-driven organization. We are grateful for Randy's many contributions and wish him the best in his retirement,' concluded Mr. Herbert. Full Year 2025 Guidance Inspire currently anticipates full year 2025 revenue guidance to be in the range of $900 million to $910 million, which represents growth of 12% to 13% over full year 2024 revenue of $802.8 million. This compares to the prior guidance range of $940 to $955 million. The company is maintaining its full year 2025 gross margin guidance of 84% to 86%. Inspire anticipates diluted net income per share guidance for the full year 2025 to be in the range of $0.40 to $0.50. This compares to the prior guidance of $2.20 to $2.30 per share. Webcast and Conference Call Inspire's management will host a conference call after market close today, Monday, August 4, 2025, at 5:00 p.m. Eastern Time to discuss these results and answer questions. To access the conference call, please preregister on Registrants will receive confirmation with dial-in details. A live webcast of the event can be accessed on A replay of the webcast will be available on starting approximately two hours after the event and archived on the site for two weeks. About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Use of Non-GAAP Financial Measures This press release includes the non-GAAP financial measures of Adjusted net income, Adjusted earnings per share ("EPS"), Adjusted EBITDA, and Adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ('GAAP'). We define Adjusted net income as net income or loss, plus items that are not indicative of our ongoing operations. Net income is the most directly comparable GAAP financial measure to adjusted net income. Adjusted EPS is calculated as adjusted net income divided by the dilutive weighted average shares outstanding. Diluted EPS is the most directly comparable GAAP financial measure to adjusted EPS. We define Adjusted EBITDA as net income or loss, less interest income, plus interest expense, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related legal expenses and other non-operating expenses less non-operating income. Net income is the most directly comparable GAAP financial measure to Adjusted EBITDA. We define Adjusted EBITDA margin in this release as Adjusted EBITDA divided by revenue. Net income margin is the most directly comparable GAAP measure to Adjusted EBITDA margin. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release. These non-GAAP financial measures are presented because we believe they are useful indicators of our operating performance. Management uses these measures principally as measures of our operating performance and for planning purposes, including the preparation of our annual operating plan and financial projections. We believe these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe these non-GAAP financial measures are useful to our management and investors as a measure of comparative operating performance from period to period. These non-GAAP financial measures should not be considered as an alternative to, or superior to, the most directly comparable GAAP financial measures, as measures of financial performance or cash flows from operations, as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management's discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our GAAP results in addition to using non-GAAP financial measures on a supplemental basis. Our definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding full year 2025 financial outlook and our expectations regarding the launch of our Inspire V neurostimulation system, including the timeline to complete the full transition to that product. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' 'future,' 'outlook,' 'guidance,' ''intend,'' ''target,'' ''project,'' ''contemplate,'' ''believe,'' ''estimate,'' ''predict,'' ''potential,'' ''continue,'' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our history of operating losses and dependency on our Inspire therapy for revenues; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire therapy or any future products we may seek to commercialize; competitive companies, technologies and pharmaceuticals in our industry; our involvement in current or future legal disputes or regulatory proceedings; our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire therapy; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; our ability to accurately forecast customer demand for our Inspire therapy and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire therapy in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; our ability to address quality issues that may arise with our Inspire therapy; our ability to successfully integrate any acquired business, products, or technologies; changes in global macroeconomic trends; challenges experienced by patients in obtaining prior authorization, our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire therapy; our business model and strategic plans for our products, technologies and business, including our implementation thereof; the impact of glucagon-like peptide 1 class of drugs on demand for our Inspire therapy; risks related to information technology and cybersecurity; our ability to commercialize or obtain regulatory approvals for our Inspire therapy, or the effect of delays in commercializing or obtaining regulatory approvals; and FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions 'Risk Factors' and "Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at and the Investors page of our website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Investor & Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ Inspire Medical Systems, Statements of Operations and Comprehensive Income (Loss) (unaudited)(in thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ 217,086 $ 195,885 $ 418,403 $ 359,895 Cost of goods sold 34,672 29,843 65,381 54,600 Gross profit 182,414 166,042 353,022 305,295 Operating expenses: Research and development 26,209 28,859 54,012 57,709 Selling, general and administrative 159,521 132,084 303,811 257,705 Total operating expenses 185,730 160,943 357,823 315,414 Operating (loss) income (3,316 ) 5,099 (4,801 ) (10,119 ) Other (income) expense: Interest and dividend income (4,486 ) (5,882 ) (9,552 ) (11,805 ) Interest expense 4 — 4 — Other expense, net 3,498 135 2,920 195 Total other income (984 ) (5,747 ) (6,628 ) (11,610 ) Income (loss) before income taxes (2,332 ) 10,846 1,827 1,491 Income taxes 1,260 1,053 2,427 1,703 Net income (loss) (3,592 ) 9,793 (600 ) (212 ) Other comprehensive income (loss): Foreign currency translation gain (loss) 191 (39 ) (109 ) (173 ) Unrealized loss on investments (22 ) (200 ) (31 ) (742 ) Total comprehensive income (loss) $ (3,423 ) $ 9,554 $ (740 ) $ (1,127 ) Net income (loss) per share: Basic $ (0.12 ) $ 0.33 $ (0.02 ) $ (0.01 ) Diluted $ (0.12 ) $ 0.32 $ (0.02 ) $ (0.01 ) Weighted average shares outstanding: Basic 29,506,807 29,728,849 29,604,043 29,672,006 Diluted 29,506,807 30,408,439 29,604,043 29,672,006 Inspire Medical Systems, Balance Sheets (unaudited)(in thousands, except share and per share amounts) June 30,2025 December 31,2024 Assets Current assets: Cash and cash equivalents $ 106,927 $ 150,150 Investments, short-term 193,968 295,396 Accounts receivable, net of allowance for credit losses of $1,229 and $880, respectively 137,687 93,068 Inventories, net 121,633 80,118 Prepaid expenses and other current assets 12,974 12,074 Total current assets 573,189 630,806 Investments, long-term 109,830 70,995 Property and equipment, net 85,274 71,925 Operating lease right-of-use assets 24,524 23,314 Other non-current assets 9,376 11,343 Total assets $ 802,193 $ 808,383 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 53,162 $ 38,687 Accrued expenses 40,197 49,814 Total current liabilities 93,359 88,501 Operating lease liabilities, non-current portion 30,909 30,039 Other non-current liabilities 111 148 Total liabilities 124,379 118,688 Stockholders' equity: Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding — — Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 29,569,477 and 29,740,176 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 29 30 Additional paid-in capital 969,903 981,043 Accumulated other comprehensive income 396 536 Accumulated deficit (292,514 ) (291,914 ) Total stockholders' equity 677,814 689,695 Total liabilities and stockholders' equity $ 802,193 $ 808,383 Inspire Medical Systems, of Non-GAAP Financial Measures (unaudited)(in thousands, except share and per share amounts)Reconciliation of GAAP Net Income (Loss) and Income per Share to Non-GAAP Adjusted Net Income and Adjusted Net Income per Share Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net income (loss) $ (3,592 ) $ 9,793 $ (600 ) $ (212 ) Stock-based compensation expense(1) 11,155 — 11,155 — Legal fees(2) 1,736 — 1,736 — Other(3) 4,046 — 4,046 — Adjusted net income (loss) $ 13,345 $ 9,793 $ 16,337 $ (212 ) Net income (loss) per share: Basic $ (0.12 ) $ 0.33 $ (0.02 ) $ (0.01 ) Diluted $ (0.12 ) $ 0.32 $ (0.02 ) $ (0.01 ) Adjusted net income per share: Basic $ 0.45 $ 0.33 $ 0.55 $ (0.01 ) Diluted $ 0.45 $ 0.32 $ 0.55 $ (0.01 ) Weighted average shares outstanding: Basic 29,506,807 29,728,849 29,604,043 29,672,006 Diluted 29,506,807 30,408,439 29,604,043 29,672,006 (1) Represents accelerated stock-based compensation expense for certain employees who are retirement eligible in accordance with the implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement. (2) These costs represent legal-related expenses related to a civil investigative demand from the Department of Justice and a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. These costs do not reflect costs associated with our normal ongoing operations. (3) Represents a non-cash impairment of a strategic investment, which does not reflect costs associated with our ongoing of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net income (loss) $ (3,592 ) $ 9,793 $ (600 ) $ (212 ) Interest and dividend income (4,486 ) (5,882 ) (9,552 ) (11,805 ) Interest expense 4 — 4 — Income taxes 1,260 1,053 2,427 1,703 Depreciation and amortization 3,414 1,383 6,458 2,222 EBITDA (3,400 ) 6,347 (1,263 ) (8,092 ) Stock-based compensation expense(4) 41,724 32,322 72,780 58,644 Legal fees 1,736 — 1,736 — Other 4,046 — 4,046 — Adjusted EBITDA $ 44,106 $ 38,669 $ 77,299 $ 50,552 (4) Total stock-based compensation expense. Reconciliation of GAAP Net Income Margin and Non-GAAP Adjusted EBITDA Margin Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net income margin(5) (2) % 5 % — % — % Interest and dividend income (2) % (3) % (2) % (3) % Interest expense — % — % — % — % Income taxes 1 % 1 % 1 % — % Depreciation and amortization 2 % 1 % 2 % 1 % Stock-based compensation expense(4) 18 % 16 % 16 % 16 % Legal fees 1 % — % — % — % Other 2 % — % 1 % — % Adjusted EBITDA margin(6) 20 % 20 % 18 % 14 % (4) Total stock-based compensation expense. (5) Net income margin is calculated as net income (loss) divided by total revenue. (6) Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total revenue.
Malaysian Reserve
01-08-2025
- Business
- Malaysian Reserve
Latest tech employment data elicits more questions, while answer clarity remains elusive, CompTIA analysis finds
Measures of tech employment a mix of positives and negatives DOWNERS GROVE, Ill., Aug. 1, 2025 /PRNewswire/ — New data on tech hiring activity continues to offer ambiguous signals on the direction of the job market, according to analysis by CompTIA, the leading global provider of vendor-neutral information technology (IT) training and certifications. Tech occupation employment, which encompasses companies in all industry sectors, increased by an estimated net new 54,000 workers in July, CompTIA analysis of U.S. Bureau of Labor Statistics (BLS) #JobsReport data reveals.1 The unemployment rate for tech occupations was 2.9% in July, up slightly from June's 2.8% rate. An estimated 6.6 million people are employed in tech occupations. Tech sector companies reduced staffing last month by a net 10,314 positions across all job role types.2 Staffing reductions were concentrated in three primary sector categories – IT and custom software services, cloud infrastructure and telecommunications. Tech manufacturing was unchanged. Complicating the picture are the now routine backward revisions to employment data due to factors often outside the control of the BLS. 'In an environment where uncertainty is the norm, the latest tech employment data is a welcome mix of some reasonably positive measures, and then of course, some lagging measures,' said Tim Herbert, chief research officer, CompTIA. Active employer job listings for tech positions totaled 440,083 in July, with 44% of the total (193,496) newly added last month, according to CompTIA analysis of Lightcast job posting data.3 Compared to June, active tech job listings fell 3% and new job listings were off 8%. Occupations in highest demand included software developers and engineers, systems engineers and architects, tech support specialists, cybersecurity engineers and architects and network engineers and architects. Listings for artificial intelligence (AI) job roles, such as AI architects, were roughly flat compared to the prior month. CompTIA's AI Hiring Index indicates relatively higher growth in hiring demand for the broad range of positions where employers require some type of AI skill to perform effectively in the job role. On a geographic basis, California, Texas and Virginia has the most job postings for tech positions, while South Carolina, Pennsylvania and Connecticut recorded modest month-over-month increases in tech occupation openings. Washington, New York, Dallas, Atlanta and Chicago were the top five metro markets by volume of tech job postings. The 'CompTIA Tech Jobs Report' is available at About CompTIA CompTIA Inc. is the leading global provider of vendor-neutral information technology (IT) training and certifications. CompTIA unlocks potential in millions of aspiring technology professionals and careers changers. Working in partnership with thousands of academic institutions and training providers, CompTIA helps students build career-ready skills through best-in-class learning solutions, industry-recognized certifications and career resources. Learn more at Media ContactSteven OstrowskiCompTIAsostrowski@ 630.678.8468 1 Monthly occupation level data from the U.S. Bureau of Labor Statistics tends to experience higher levels of variance and volatility.2 Labor market data from the U.S. Bureau of Labor Statistics and employer job postings from Lightcast may be subject to backward revisions.3 Active job postings include new postings added by employers in the latest month and open postings carried over from previous months.
